“One pill, once daily”: what clinicians need to know about Atripla™

Review

(2145) Views  (361) Full article downloads

Authors: Patrick G Clay, Tracey AH Taylor, Alan G Glaros, MaryPeace McRae, Charlott Williams, et al

Published Date April 2008 Volume 2008:4(2) Pages 291 - 302

DOI: http://dx.doi.org/10.2147/TCRM.S1708

Patrick G Clay^1,2, Tracey AH Taylor¹, Alan G Glaros³, MaryPeace McRae¹, Charlott Williams², Don McCandless¹, Maurice Oelklaus⁴

¹Department of Pharmacology/Microbiology; ²Department of Clinical Research; ³Division of Basic Sciences; ⁴College of Medicine, Kansas City University of Medicine and Biosciences, Kansas City, MO, USA

Abstract: As the number of persons chronically prescribed antiretrovirals has grown and the realization that antiretrovirals are required to be continued for life, pharmaceutical manufacturers have developed new classes of agents, improved the pharmacokinetics of marketed products through dosing reformulations, and in an effort to maximize success with respect to adherence, compiled into a single dosing unit all necessary elements for an antiretroviral regimen. Atripla™ represents the first ever fixed-dose combination antiretroviral available. This article reviews currently available data on this agent, the impact of resistance on clinical use and implementation, as well as extensive descriptions of the pharmacokinetics, adverse effects and drug-interactions warranting consideration. Whether beginning in a naïve patient or switching from other regimens for tolerability issues, Atripla™ represents a viable option. Its demonstrated advantages with respect to lipid and hematologic parameters and equivalent incidence of renal toxicity are tempered by the findings of bone mineral density decreases, however. Combining multiple mechanisms of action in a single dosing unit appears to improve efficacy, increase the likelihood for adherence and maintain viral suppression compared to administering these agents independently. It is suggested other pharmaceutical companies assess the potential to replicate this for the remaining antiretrovirals.

Keywords: Atripla™, antiretrovirals, HIV